Ronald Balkissoon, MD
Pulmonary Disease · Denver, CONPI 1013926468
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $967,398 of the $1,205,080 with a category attached, or 80.3%. 11 manufacturers reported payments, led by GSK at 48.4% of the total. Reporting peaked in 2019 at $365,763 and has fallen 70.5% since, to $108,039 in 2025. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 965 payments — averaging $1248.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$584K
- AstraZeneca$322K
- Regeneron Healthcare Solutions, Inc.$150K
- Sanofi$100K
- Merck$13K
- Sunovion Pharmaceuticals Inc.$11K
- plus $25K from 5 others
What the payments were for
- Consulting fees$103,7669%
- Speaking & faculty fees$967,39880%
- Travel & lodging$114,58910%
- Food & beverage$19,2462%
- Education$630%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 421 | $583,630 |
| AstraZeneca | 289 | $321,823 |
| Regeneron Healthcare Solutions, Inc. | 127 | $150,349 |
| Sanofi | 75 | $99,543 |
| Merck | 13 | $13,279 |
| Sunovion Pharmaceuticals Inc. | 7 | $11,238 |
| Genentech USA, Inc. | 15 | $9,259 |
| Novartis | 5 | $7,077 |
| Bayer | 11 | $6,714 |
| Boehringer Ingelheim | 1 | $2,150 |
| Bristol Myers Squibb | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$253,974
- DUPIXENT$235,199
- NUCALA$139,685
- FASENRA$133,607
- BREZTRI$130,012
- AREXVY$72,331
- AIRSUPRA$37,116
- ANORO$18,141
- LONHALA MAGNAIR$11,151
- SHINGRIX$10,400
- XOLAIR$9,867
- BEVESPI AEROSPHERE$5,550
- DALIRESP$3,730
- ANORO ELLIPTA$3,718
- GILENYA$386
How this compares
$1,205,080 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $27,765 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $18,115 |
| Azelastine Hcl | 53 | $1,732 |
| Famotidine | 155 | $1,337 |
| Baclofen | 170 | $1,179 |
| Pantoprazole Sodium | 83 | $1,022 |
| Dexamethasone | 65 | $889 |
| Esomeprazole Magnesium | 22 | $727 |
| Azithromycin | 37 | $545 |
| Omeprazole | 33 | $493 |
| Fluticasone Propionate | 39 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $583,630 | $27,76544 claims |
| AstraZenecaBreztri Aerosphere | $321,823 | $18,11528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Barry MakeDenver$162K
- Amy OlsonDenver$117K
- Robert SandhausDenver$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.